B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT

Key Points

• B. Metzler seel. Sohn & Co. AG bought a new stake of 15,382 shares (~$944,000) in PTC Therapeutics during the 3rd quarter, per the latest 13F filing.
• Company insiders sold heavily last quarter — a total of 183,926 shares worth $13.58M (including CAO Christine Utter's 2,494-share sale and Neil Almstead's 3,989-share sale) while insiders now own about 5.5% of the stock.
• PTC reported a sharp miss on results (quarterly EPS of -$1.67 vs. -$0.21 expected and revenue of $164.7M vs. $281.5M est., down 22.7% YoY), though analysts maintain a consensus rating of "Moderate Buy" with a $82.79 price target.

B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,382 shares of the biopharmaceutical company's stock, valued at approximately $944,000.

Several other large investors have also recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its position in PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. raised its holdings in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 249 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in PTC Therapeutics by 42.1% in the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 295 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 814 shares in the last quarter. Finally, Globeflex Capital L P purchased a new stake in shares of PTC Therapeutics during the second quarter valued at approximately $91,000.

Insider Buying and Selling at PTC Therapeutics

In other news, CAO Christine Marie Utter sold 2,494 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $172,983.84. Following the completion of the sale, the chief accounting officer owned 70,199 shares of the company's stock, valued at $4,869,002.64. This represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Neil Gregory Almstead sold 3,989 shares of PTC Therapeutics stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $63.38, for a total transaction of $252,822.82. Following the transaction, the insider owned 2,737 shares in the company, valued at $173,471.06. This represents a 59.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 183,926 shares of company stock worth $13,577,065. 5.50% of the stock is owned by corporate insiders.

PTC Therapeutics Price Performance

NASDAQ PTCT opened at $65.67 on Thursday. The stock has a market capitalization of $5.44 billion, a price-to-earnings ratio of 8.48 and a beta of 0.51. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The business's fifty day moving average price is $72.23 and its 200-day moving average price is $69.69.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The firm had revenue of $164.68 million during the quarter, compared to the consensus estimate of $281.45 million. During the same period in the previous year, the firm earned ($0.85) EPS. The business's revenue was down 22.7% on a year-over-year basis. Equities research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. TD Cowen reissued a "hold" rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Bank of America lowered their price objective on PTC Therapeutics from $97.00 to $93.00 and set a "buy" rating on the stock in a research report on Friday, February 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of PTC Therapeutics in a report on Friday, February 20th. Morgan Stanley boosted their price target on PTC Therapeutics from $90.00 to $92.00 and gave the stock an "overweight" rating in a research note on Monday, February 23rd. Finally, Barclays reaffirmed an "overweight" rating and set a $120.00 price target on shares of PTC Therapeutics in a report on Monday, February 23rd. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, PTC Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $82.79.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.